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Advances in allogeneic hematopoietic cell transplantation for sicklecell disease have improved outcomes, but there is limited analysisof healthcare utilization in this setting. We hypothesized that,
compared to late transplantation, early transplantation (at age <10 years)
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improves outcomes and decreases healthcare utilization. We performed a retrospective study of children
transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate
and Cox models were used to estimate associations of demographics, sickle cell disease severity, and
transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon,
Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161
patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was
significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95%
CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95%
CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those
translanted late (HR 1.9, 95% CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5,
95% CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant
cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recip-
ients of matched sibling donor grafts and those with low severity disease compared to those with other
types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was
demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant
data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001),
length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively
in young children without severe disease and an available matched sibling to provide conclusive evi-
dence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care
indicates that transplantation  may provide a sustained decrease in healthcare costs over time.
Introduction 
Sickle cell disease (SCD) affects approximately 100,000
people in the United States of America (USA) with 2,000
new cases detected via newborn screening annually.
There is a lack of clinical predictors to estimate overall
outcomes of SCD-associated morbidities, including
painful crises and organ dysfunction, which respond vari-
ably to medical management, have a devastating impact
on quality of life, and can lead to premature death.1 As a
result, many people with SCD are left with sequelae of
the disease and its complications. Allogeneic hematopoi-
etic cell transplantation (alloHCT) remains the only estab-
lished curative option for these individuals.
Despite mounting evidence of rising alloHCT success
rates over time, such that the 5-year disease-free survival
in children with SCD is now 92%, many still regard
alloHCT as an experimental therapy, only for patients
with severe disease.2,3 The indications for alloHCT
remain unclear for non-transplant providers when com-
pared to the benefits of medical management.4 In addi-
tion, a recent retrospective study from Belgium suggest-
ed that patients with SCD managed medically with
hydroxyurea may have a better survival than those treat-
ed with alloHCT.5
However, short-term improvements in outcome with
medical therapy must be balanced against a disease with
an unpredictable clinical course and substantial impact on
healthcare utilization. USA individuals with SCD account
for an estimated $1.6 billion per year in healthcare costs.6
SCD ranked fifth among the top ten diagnoses of hospital
stays among Medicaid super-utilizers.7 The substantial
healthcare utilization and cost of SCD-related morbidity
suggests that a greater focus on curative approaches for
this disease is needed. 
AlloHCT, when successful, can be curative, but also car-
ries the risks of death and substantial morbidity from
chronic graft-versus-host disease (GvHD). In addition, the
initial cost of alloHCT represents a significant financial
burden of approximately $400,000 in the transplant year.8
This research investigates alloHCT for pediatric SCD
using a comprehensive, systematic database analysis
exploring patient-, disease-, and transplant-related vari-
ables that may reduce healthcare utilization over time
while sustaining excellent clinical outcomes. The findings
may provide transplant and non-transplant physicians
with additional information to help choose between rec-
ommending medical therapy and alloHCT. 
Methods
Data sources
Outcomes analysis
The Center for International Blood and Marrow Transplant
Research (CIBMTR) database contains alloHCT data for recipients
and their donors. Data are collected prior to and at various inter-
vals post-alloHCT. Upon CIBMTR registration, a weighted ran-
domization scheme selects a subset of patients for more detailed
data collection in comprehensive research forms (CRF) which pro-
vide more specific transplant-related data (SCD complications,
pre-transplant therapy, etc.) (Online Supplementary Figure A1). 
Healthcare utilization analysis
CIBMTR data on all alloHCT recipients are submitted as trans-
plant essential data (TED) (Online Supplementary Figure A2). TED
forms record donor and recipient demographic, clinical, and trans-
plant data but lack specific CRF data.
The Pediatric Health Information System (PHIS; Children’s
Hospital Association, Overland Park, KS, USA) records the corre-
sponding inpatient healthcare utilization data. PHIS, a confidential
database of 43 member hospitals in the USA (Online Supplementary
Figure A3), has participating hospitals submit de-identified data
with an encrypted medical record number for identification of
readmissions at the same hospital. Institutional and patient-specif-
ic information, including patient’s age, date of service, visit codes,
length of stay (LOS), adjusted costs, and daily billing data, are col-
lected. The PHIS has been merged for similar research purposes
including a number of recent scientific publications.9
Merging and validating datasets
Patients in the PHIS database who underwent alloHCT for SCD
during the study period were identified utilizing International
Classification of Diseases version 9 (ICD9) and alloHCT diagno-
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Table 1. Characteristics of USA pediatric patients (age ≤21) receiving first allogeneic hematopoietic cell transplant for sickle cell disease.
Variable Outcomes analysis (CRF)     HCU analysis (TED/PHIS)    
N (%) N (%)
Number of patients 161 183
Patient-related
Age, median, years 10 (<1-21) 9 (<1-20)
Age at transplant, years                                                                                                                                                                             
<10                                                                                                                          86 (53)                                                                  100 (55)
≥10 75 (47) 83 (45)
Gender
Male 81 (50) 101 (55)
Female 80 (50) 82 (45)
Race                                                                                                                                                                                                                
African-American                                                                                                142 (88)                                                                155 (85)
Other/missing                                                                                                       19 (22)                                                                   28 (15)
Karnofsky/Lansky score 
prior to transplant, %
>90 91 (57) 164 (90)
≤90 52 (32) 2 (1)
Missing 18 (11) 17 (9)
Disease-related
Chronic transfusion Not recorded
No 53 (33) -
Yes 103 (64) -
Missing 5 (3) -
Hydroxyurea                                                                                                                                                                                     Not recorded
No                                                                                                                            82 (51)                                                                        -
Yes                                                                                                                           72 (45)                                                                        -
Missing                                                                                                                      7 (4)                                                                           -
Sickle cell related complications
Stroke 62 (39) 29 (16)
Acute chest syndrome 85 (53) 46 (25)
Recurrent vaso-occlusive pain 89 (55) 134 (73)
Transplant-related
Time from diagnosis to transplant (months) 112 (7-242) 109 (10-227)
Transplant indication                                                                                                                                                                     Not recorded
Stroke                                                                                                                     47 (29)                                                                        -
Acute chest syndrome                                                                                        19 (12)                                                                        -
Recurrent vaso-occlusive pain                                                                          35 (22)                                                                        -
Excessive transfusion requirements                                                              17 (11)                                                                        -
Other*/missing                                                                                                     43 (26)                                                                         -
Conditioning regimen
Myeloablative 96 (60) 121 (66)
Reduced intensity 54 (33) 58 (32)
Non-myeloablative 11(7) 4 (2)
Graft source                                                                                                                                                                                                 
Bone marrow                                                                                                        97 (60)                                                                 144 (79)
Peripheral blood                                                                                                    9 (6)                                                                      4 (2)
Cord blood                                                                                                             55 (34)                                                                   35 (19)
Donor/recipient CMV match
-/- 47 (29) 55 (30)
-/+ 25 (16) 20 (11)
+/- 31 (19) 22 (12)
+/+ 41 (25) 51 (28)
Missing 17 (11) 35 (19)
Donor type                                                                                                                                                                                                    
Cord blood                                                                                                             55 (34)                                                                  35 (19)
Related                                                                                                                   22 (40)                                                                  15 (43)
Unrelated                                                                                                               33 (60)                                                                  20 (57)
HLA identical sibling                                                                                            67 (42)                                                                 126 (69)
Well-matched unrelated                                                                                     27 (17)                                                                   10 (5)
Other unrelated                                                                                                    11 (7)                                                                     7 (4)
Missing                                                                                                                    1 (<1)                                                                      5 (3) continued on next page
sis-related group (DRG) codes (282.6 and 1803, respectively) as
well as PHIS procedure codes. These patients were identified
within the CIBMTR using a probabilistic algorithm. This process
occurred under the guidance of the CIBMTR via the National
Marrow Donor Program institutional review board.  
TED data were merged with PHIS data to determine risk factors
and clinical outcomes associated with healthcare utilization
(Online Supplementary Figure A4). A target of 85% merge accuracy
was set based on the available database population and previously
published reports.9-11 Once linked, the merge accuracy was
assessed by performing institutional level validation under an
existing pilot institutional review board process.8 This validation
confirmed 100% patient identification in this subset. SCD-related
complications identified in the PHIS were validated against CRF
data, where available, and showed concordance. 
Determination of the severity of sickle cell disease
TED/PHIS variables were used to determine SCD severity.
Younger patients (age <10 years) without disease sequelae were
considered low risk. Younger patients with disease sequelae or
older patients (age ≥10 years) without disease sequelae were con-
sidered moderate risk. Older patients with disease sequelae or
patients of any age with stroke were considered high risk. Disease
sequelae were defined as any episode of acute chest syndrome,
and/or three or more vaso-occlusive crises requiring hospitaliza-
tion in 1 year.12
Variables and outcomes
Outcomes analysis
The study population consisted of children 21 years or younger
who had undergone alloHCT for SCD in the USA between 2000-
2013 and for whom CRF data were available. The CRF provided
information on clinical risk factors and outcomes including overall
survival, graft failure, grade II-IV acute GvHD, chronic GvHD, and
GvHD-related event free survival (GREFS). GREFS was defined as
the survival free of graft failure, chronic GvHD, or death and was
used to better assess the post-alloHCT morbidity and associations
of clinical risk factors with outcomes.  
Healthcare utilization analysis
The total adjusted cost reported to the PHIS is based on a fixed
hospital-wide ratio of cost to charge adjusted by geographical
location. Adjusted costs for each service unit or department (clini-
cal, pharmacy, imaging, etc.) were reported using service-specific
ratios of cost to charge. Charges in the PHIS database were adjust-
ed for the wage and price index (published annually in the Federal
Register) and reported from the hospital perspective. Total adjust-
ed costs were determined for all inpatient admissions for each
patient and include direct medical costs, excluding provider fees,
incurred. Indirect costs, outpatient costs, and costs incurred at
non-PHIS hospitals were not captured.
Adjusted cost data only were analyzed as the primary outcome
of interest because charges and reimbursements vary across each
institution and state. Patients without available adjusted cost data
were excluded (n=7). Zero-dollar research or study-related costs,
reflecting largely workup, medication, or laboratory-related
account credits, were included in the analysis. Additional health-
care utilization outcomes included number of admissions and
LOS. PHIS data were used for descriptive analyses of the selected
cohort of patients throughout all the study periods. 
Healthcare utilization for the initial alloHCT admission (con-
ditioning to first recorded discharge) and alloHCT year (condi-
tioning to day +365) was described and considered separately in
the analyses. Likewise, the pre-alloHCT period (2 years preced-
ing transplant through to the day of transplant conditioning) and
the post-alloHCT period (2 years from day +366 onward) were
analyzed separately (Online Supplementary Figure B). 
Analysis of allogeneic hematopoietic cell transplant year
Factors influencing healthcare utilization during the alloHCT
year were analyzed using the following TED clinical variables -
age at transplant, gender, performance status, recipient
cytomegalovirus status, income level, insurance, distance from
center, SCD complications, donor type, graft source, conditioning
regimens, and transplant year. A secondary analysis of disease
severity and healthcare utilization was also performed. 
Pre- and post-allogeneic hematopoietic cell transplantation com-
parison
To standardize costs for comparisons, the total adjusted cost per
30 hospital days was calculated for each patient with both pre- and
post-alloHCT inpatient admissions and used as the primary
healthcare utilization outcome. The change in an individual
patient's healthcare utilization pre- and post-alloHCT was com-
pared. This change in healthcare utilization was also analyzed by
disease severity.
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Year of transplant
2000-2006 42 (26) 54 (30)  
2007-2013 119 (74) 129 (70)
GvHD prophylaxis                                                                                                                                                                                        
FK506 ± MMF or MTX                                                                                         57 (36)                                                                  40 (22)
CSA ± MMF or MTX                                                                                             89 (55)                                                                 134 (73)
Others**/missing                                                                                                  15 (9)                                                                     11 (5)
Median follow-up of survivors (range), months 49 (3-138) 49 (11-145)
Well matched- 10/10 HLA match; other unrelated – mismatched or <10/10 HLA match; CRF: comprehensive research form; HCU: healthcare utilization; TED: transplant essential
data; PHIS: pediatric health information system; CsA: cyclosporine, FK506: tacrolimus; CMV: cytomegalovirus; CY: cyclophosphamide; ATG: antithymocyte globulin;FLUD-fludara-
bine; BU: busulfan; MEL: melphalan; MMF-mycophenolate mofetil; MTX: methotrexate *abnormal transcranial Doppler(TCD)-magnetic resonance imaging angiography with nar-
rowing of supraclinoid portions of the internal carotid arteries bilatecally (n=1); abnormal TCD (n=1); acute chest syndrome (ACS); pain; transfusions (n=1); best long-term, life-
long option for patient (n=1); both ACS and pain crisis (n=1); cardiomyopathy/pulmonary stenosis (n=1); cerebral vasculopathy (n=1); combination of ACS and pain crisis
(chronically ill) (n=1); cranial vasculopathy therefore stroke prevention (n=1); cure sickle cell (n=1); develop allo antibodies, increasing hgb, decreased response to hydroxyurea
(n=1); elevated transcranial Doppler (n=1); extensive complications from sickle cell (n=1); family wanted to move back to Nigeria where there is not modern care nor safe trans-
fusion(n=1); fever, ileus and mild ACS (n=1); improved quality of life (n=1); increased frequency of pain crisis, at significant risk end organ damage anddysfunction in adulthood
(n=1); liver transplant (n=1); matched sibling and hiistory of pain crisis (n=1); osteonecrosis/requiring hip replacement neuropathy-vision loss (n=1); pain;avascular necrosis;
magnetic resonance imaging changes to correct SCD (n=1); parents wanted a cure for their child’s SCD (n=1); presence of silent infarcts on magnetic resonance imaging (n=1);
rare disease type (n=1); SCD (n=1); **cor+methotrexate (n=1), methotrexate (n=1)
continued from the previous page
Statistical analysis
Outcomes analysis
After documenting descriptive statistics, Cox propor-
tional hazards modeling of CRF level data determined the
impact of risk factors on alloHCT outcomes. Due to low
event rates and small sample sizes, only bivariate analyses
involving one explanatory variable at a time were per-
formed. The cumulative incidences of acute GvHD and
chronic GvHD were calculated using a competing risk
framework.
Healthcare utilization analysis
TED/PHIS data were evaluated to identify whether
demographic factors, SCD severity, or alloHCT variables
correlate with healthcare utilization changes during the
alloHCT year using Wilcoxon, Kruskal-Wallis, or linear
trend tests. Healthcare utilization pre- and post-alloHCT
was compared using the Wilcoxon signed rank test for
continuous variables and the McNemar test for binary
variables. Finally, the impact of SCD severity on health-
care utilization across these two time periods was exam-
ined by Poisson regression for number of visits and LOS.
Total adjusted cost were analyzed by linear regression. All
analyses were performed using SAS version 9.3 statistical
software (Cary, NC, USA).
Results
Outcomes analysis 
Demographics
CRF data were available for 161 patients with a median
age of 10 years (range <1-21) of whom 50% were female
(Table 1; Online Supplementary Table A). The majority
(84%) of patients had the HbSS genotype.  The most com-
monly documented transplant indication was stroke (29%)
followed by recurrent vaso-occlusive crises (22%).
However, 39% had stroke as a documented SCD complica-
tion, 55% vaso-occlusive crises, and 53% acute chest syn-
drome. The majority of patients reported use of medical
therapy, hydroxyurea (45%) and chronic transfusions
(64%). The most common source of a graft for transplan-
tation was a matched sibling donor (MSD) (42%) and the
majority of patients received myeloablative conditioning
(60%).
Transplant outcomes
The 2-year overall survival was 90% [95% confidence
interval (CI): 85-95%]: 96% (95% CI: 89-100%) for cord
blood transplant (CBT), 94% (95% CI: 86-98%) for MSD
transplants, and 74% (95% CI: 54-90%) for transplants
from well-matched unrelated donors (MUD) (P=0.002)
(Online Supplementary Table B and Online Supplementary
Figure C). All 16 deaths occurred among children with pre-
alloHCT complications of SCD and were due to organ
failure (37.5%), infections (25%), GvHD (6.2%), and
other/unknown causes (31.2%) (Online Supplementary
Table C). The majority of deaths (62.5%) occurred during
the alloHCT year; six patients died after day +365 (2 from
organ failure, 1 from infection, 1 from sickle cell-associat-
ed vasculopathy, and 2 from a missing/other unspecified
cause).
The cumulative incidence of acute GvHD at day 100
was 14% (95% CI: 9-20%), and chronic GvHD developed
in 31% (95% CI: 23-38%) at 2 years. Of those with chron-
ic GvHD, 64% had extensive disease with over half hav-
ing a MSD (n=9) or MUD (n=11).  The 2-year GREFS was
64% (95% CI: 56-71%).
Bivariate analysis
Age ≥10 years and use of a MUD showed significant
negative associations with outcomes (Table 2). The use of
cyclosporine-A prophylaxis and year of alloHCT exhibit-
ed significant associations with chronic GvHD-related
outcomes (Table 2). 
Healthcare utilization analysis
Demographics
Combined TED/PHIS data were available for 183
patients with a median age of 9 years (range: <1-20) of
whom 45% were female (Table 1). With regards to SCD
complications, 73% had vaso-occlusive crises, 25% had
Transplant risks and utilization for SCD
haematologica | 2017; 102(11) 1827
Table 2. Cox regression model of outcomes with patient- and transplant- related variables as reported in CRF data (n=161).
Variable Mortality (n=16) Graft failure (n=3) aGVHD (n=33) cGVHD (n=44) GREFS (n=54)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age (≥10 years) *21.21 (2.80-160.76) *1.61 (1.17-2.21) *2.63 (1.07-6.45) *1.92 (1.05-3.50) *2.2 (1.26-3.82)
Gender (female) 3.09 (1.00-9.57) 1.21 (0.88-1.66) 1.87 (0.78-4.46) 1.49 (0.82-2.73) 1.65 (0.95-2.85)
Performance status (<90%) 1.03 (0.34-3.06) 1.11 (0.78-1.58) 1.74 (0.75-4.01) 1.67 (0.91-3.06) 1.57 (0.90-2.74)
SCD complications (>2) 1.09 (0.38-3.13) 1.09 (0.78-1.54) 0.79 (0.33-1.91) 1.89 (0.96-3.74) 1.64 (0.90-3.01)
Hydroxyurea 2.71 (0.92-7.93) 1.21 (0.89-1.69) 1.72 (0.73-4.03) 1.62 (0.87-3.02) *1.77 (1.00-3.12)
Chronic transfusion 1.96 (0.55-6.94) 0.8 (0.57-1.12) 1.13 (0.46-2.76) 1.11 (0.58-2.13) 1.21 (0.66-2.2)
CMV+ recipient 1.59 (0.56-4.46) 0.92 (0.67-1.26) *2.75 (1.06-7.09) 1.31 (0.72-2.39) 1.37 (0.80-2.36)
MUD vs.MSD *5.88 (1.71-20.19) 1.93 (1.22-3.06) *4.36 (1.43-13.34) *2.53 (1.18-5.41) *3.00 (1.51-5.96)
CBT vs.MSD 0.92 (0.20-4.1) *0.50 (0.34-0.74) 1.56 (0.47-5.11) 0.94 (0.43-2.05) 1.07 (0.52-2.16)
CSA vs. FK506 prophylaxis *0.33 (0.12-0.91) 1.02 (0.72-1.43) 0.68 (0.29-1.6) *0.48 (0.26-0.88) *0.49 (0.28-0.86)
AlloHCT after 2006 2.90 (0.66-12.78) 1.11 (0.77-1.58) 3.75 (0.88-16.03) *2.81 (1.18-6.65) *2.25 (1.10-4.61)
NMA/RIC vs. MA 1.52 (0.57-4.06) 1.27 (0.92-1.76) 1.17 (0.51-2.71) 1.26 (0.70-2.28) 1.03 (0.60-1.77)
CRF: comprehensive research form; aGvHD: grade 3-4 acute graft-versus-host disease; cGvHD: chronic graft-versus-host disease; GREFS: the survival free of graft failure, chronic
graft-versus-host disease, or death; SCD: sickle cell disease; CMV: cytomegalovirus; MUD: matched unrelated donor; MSD:  matched sibling donor; CSA: cyclosporina; alloHCT: allo-
geneic hematopoietic cell transplant; NMA: non-myeloablative; RIC: reduced intensity conditioning; MA: myeloablative conditioning. *P≤0.05
acute chest syndrome, and 16% had a stroke prior to
alloHCT. This translated into 19.7% with low severity
disease, 36.6% with moderate severity, and 43.7% with
high severity disease (Online Supplementary Table D). The
majority of patients received MSD alloHCT (69%) and a
myeloablative regimen (66%). Complete cost data were
available for 176 of the 183 patients. 
Allogeneic hematopoietic cell transplantation admission
The median total adjusted cost per patient was $380,320
[interquartile range (IQR): $297,710-$563,462] with a
median LOS of 39.5 days (IQR: 31-53) (Table 3). The high-
est costs were associated with room and nursing charges
followed by pharmacy costs (Online Supplementary Figure
D). 
Allogeneic hematopoietic cell transplantation year
The median total adjusted cost per patient was $467,747
(IQR: $344,029-$799,219) with a median LOS of 52 days
(IQR: 38-72) (Table 3). Again, the highest costs were asso-
ciated with room and nursing charges followed by phar-
macy costs (Online Supplementary Figure D).
During the alloHCT year, age ≥10 years and total adjust-
ed cost per 30 days were not significantly associated
(P=0.775) (Table 4). Total adjusted cost was also not asso-
ciated with income level, insurance type, or distance from
transplant center (P=0.417, 0.918, and 0.253, respectively).
The total adjusted cost per 30 days was lower for MSD
transplants than for CBT or MUD transplants (P<0.001).
CBT was associated with a higher total adjusted cost per
30 days compared to bone marrow transplants (P=0.004).
Increased total adjusted cost per 30 days were associated
with prior stroke (P=0.004) and vaso-occlusive crises
(P=0.009) but not acute chest syndrome (P=0.291).
Overall, total adjusted cost per 30 days increased with
SCD severity (P=0.022). 
Pre- and post-allogeneic hematopoietic cell transplantation
Two-year inpatient healthcare utilization data were
available for 134 pre-alloHCT patients and 45 post-
alloHCT. The median total adjusted cost per patient was
$56,416 (IQR: $32,848-$103,270) pre-alloHCT; this
decreased to $33,112 (IQR: $14,291-$161,959) post-
alloHCT (Table 3). The highest adjusted costs during
these periods were associated with room and nursing
charges followed by laboratory costs (Online
Supplementary Figure D). 
Only 41 patients were admitted to the hospital during
both pre- and post-transplant periods: healthcare utiliza-
tion was significantly reduced with total adjusted cost per
30 days decreasing from $9,393 (IQR: $4,595-$31,291) to
$1,873 (IQR: $571-$6,504) (P=0.008) (Figure 1). Of these,
30 patients had high severity disease and had a significant
reduction in healthcare utilization (admissions P<0.001,
LOS P<0.001, cost P=0.002) (Online Supplementary Table E).  
Discussion
Substantial advances in alloHCT for SCD have been
made in the past two decades; nevertheless, the eligibility
of patients, especially those without severe disease,
remains controversial. This study provides additional
insight into eligibility as alloHCT outcomes were favor-
ably linked to age and donor type suggesting that early
alloHCT, before the age of 10 years, and MSD alloHCT
have optimal outcomes with the latter also showing a sig-
nificant healthcare utilization advantage. These outcomes
are in keeping with a recent report from an international
study of adult and pediatric MSD recipients describing
lower event-free survival rates with increasing age at
transplantation and support the recent expert panel rec-
ommendation of early alloHCT, prior to the onset of SCD
complications, for children with SCD and an available
MSD.13,14
MSD alloHCT is not, however, a viable option for many
patients, as fewer than 25% will have a suitable HLA-
matched donor, necessitating MUD alloHCT for severe
disease. Among patients undergoing MUD alloHCT, high-
er GvHD risk could be hypothesized as the etiology of
poorer outcomes and increased healthcare utilization of
older recipients.13,15-17 Although the GvHD-related mortali-
ty rate in this study is lower than that in published reports,
the low percentage of deaths after day +365 may mitigate
S.D. Arnold et al.
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Figure 1. Comparison of 2-year pre- and post-allo-
geneic hematopoietic cell transplant inpatient health-
care utilization per 30 days as reported in the
Pediatric Health Information System (n=41). Pre-
alloHCT: the 2 years preceding transplant through to
the day of transplant conditioning; Post-alloHCT:  day
+366 onward; alloHCT: hematopoietic cell transplant;
PHIS: Pediatric Health Information System: visits: inpa-
tient admissions; LOS: length of stay.
the mortality associated with chronic GvHD.  However,
the 26% mortality among the MUD alloHCT patients
remains well over the 5% mortality threshold accepted by
most parents and adolescents for the cure of SCD, as
recently published.18 Efforts are still needed to elucidate
more precisely the cause of death (unknown cause in
31%) and transplant-related mortality, especially among
patients who died after the alloHCT year, in order to
improve transplant procedures to prevent these complica-
tions. Our findings support the current practice of restrict-
ing MUD alloHCT to individuals with severe disease.19
The results of the analysis of donor type were consistent
with published reports and indicated that the overall sur-
vival of patients treated with CBT is similar to that of
recipients of MSD bone marrow; however, healthcare uti-
lization was higher with CBT.20 Many of the drawbacks of
CBT have been associated with insufficient cell dose.
Ongoing research into cord blood expansion may mitigate
this limitation and the associated healthcare utilization by
reducing the delay in engraftment.21-23 However, this
cohort of both related and unrelated CBT showed no sta-
tistical difference in GREFS or other GvHD outcomes,
with a lower cost compared to MUD, suggesting that
more analysis is needed to determine the optimal donor
type if a MSD is unavailable.  
Donor type and SCD severity had a significant impact
on both outcomes and healthcare utilization, such that
patients with high severity disease and MUD had poorer
outcomes and increased healthcare utilization. The corre-
lation of healthcare utilization and disease severity, not
age, is unclear but may suggest that healthcare utilization
is linked to management of persistent SCD complications
after alloHCT. Although some end-organ disease is
reversible after alloHCT, complications of chronic lung
disease and pain can persist in the first year post-
alloHCT.24 These complications correlate with increased
healthcare utilization in individuals with SCD.25 In addi-
tion, severe disease remains an indication for MUD
alloHCT research trials suggesting this as a possible con-
founder in healthcare utilization analysis. MUD outcomes
associated with degree of HLA matching, supportive care
measures, and infection must also be considered in more
detail.16 Understanding and mitigating risk factors associ-
ated with poor outcomes and increased healthcare utiliza-
tion following MUD alloHCT is needed because improve-
ments in unrelated alloHCT clinical outcomes have the
potential to have the greatest clinical and financial impact.
The healthcare utilization analysis also described varia-
tions over time with a subset of patients having a signifi-
cant reduction in healthcare utilization pre- and post-
alloHCT. However, the current sample size and/or 2-year
time period may not be sufficient to document a change in
inpatient healthcare utilization for the entire population of
patients. Donor type variations (e.g., CBT) and disease
severity within our small sample size likely have a role;
more robust analysis is ongoing to understand this phe-
nomenon better.  In addition, outpatient healthcare uti-
lization was not described which may account for the
substantial reduction of data available for pre- and post-
alloHCT analysis. However, previous publications on
healthcare utilization in this population indicated that out-
patient costs remained flat pre- and post-alloHCT.8
Limitations
This is a retrospective study and analysis is therefore
limited to variables and data collected by the CIBMTR at
the time of alloHCT. This limitation is somewhat mitigat-
ed by using multiple sources of data (PHIS and CIBMTR,
both TED and CRF forms) to increase sample size and
data availability or quality. Retrospective studies also do
not allow control of exposures (pre-alloHCT treatment,
conditioning, etc.) which may influence outcomes.
Bivariate and multivariate analyses can elucidate
cofounders; however, due to sample size and low event
rates, multivariate analysis was not performed in this
study. However, univariate analysis was used to docu-
ment the impact of these exposures on outcomes. 
The retrospective nature of this database study also
does not allow for comparison to controls with SCD who
have not been transplanted or incorporation of prospec-
tive metrics including quality of life in the analysis.
Previous studies have documented the quality of life
improvements gained after alloHCT for SCD.26,27 Other
studies have described significant quality of life differ-
ences between non-transplant interventions such as
chronic transfusion and hydroxyurea.1,28 Outcomes and
cost of care for children have been well documented, with
a recent analysis of management with hydroxyurea based
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Table 3. Inpatient healthcare utilization analysis as reported over time in the PHIS.
Time period Median number Median length Median total
of inpatient admissions of stay per patient adjusted
per patient (IQR) [days (IQR)] cost per patient (IQR)
Pre-alloHCT (n=134) 3 (1-6) 9 (4-18) $56,416 
(32,848-103,270)
AlloHCT admission - 40 (32-53) $380,320 
(n=176) (297,711-563,462)
AlloHCT year 2 (1-4) 52 (39-73) $467,747 
(n=176) (344,029-799,220)
Post-alloHCT 2 (1-4) 8 (3-17) $33,112
(n=45) (14,291-161,960)
PHIS: Pediatric Health Information System; alloHCT: allogeneic hematopoietic cell transplant; Pre-alloHCT - the 2 years preceding transplantation through to the day of transplant
conditioning; AlloHCT admission: conditioning to first recorded discharge; AlloHCT year: conditioning to day +365, Post-alloHCT: day +366 onward; IQR: interquartile range.
on Medicaid claims data suggesting that lifetime costs of
care may be influenced by the age of hydroxyurea initia-
tion.5,29 These data largely demonstrate the substantial life-
time costs associated with caring for individuals with SCD
and the need to compare costs across the various available
treatment options.6 Collectively these findings suggest a
multicenter case control study incorporating quality of life
is needed to truly understand the full impact of alloHCT
on outcomes and healthcare utilization. Prospective stud-
ies, including STRIDE2 (NCT02766465), are underway to
fill this gap in knowledge of alloHCT for SCD.
The study includes a population that is heterogeneous
for donor type, graft source, and conditioning regimen.
Analysis of this complex group reflects the current clinical
paradigm and its potential to influence healthcare utiliza-
tion; however, diversity does introduce confounders. A
recent study showed that conditioning regimen does not
influence outcomes, and graft source only influences over-
all survival, while age and year of transplant influence
both overall and event-free survival.13 Survival outcomes
of this cohort are similar to this and other previously pub-
lished estimates; these findings suggest that the hetero-
geneity of our cohort had limited influence on the out-
comes analysis.
The study focuses on a pediatric population which is
unique in that children are largely less affected by the dis-
ease than their adult counterparts and alloHCT has quite
a different long-term impact. Certainly, efforts to offer
early MSD alloHCT will have a significant effect on adult
care; in the meantime, a large number of adults live with
SCD. Therefore, efforts to better understand the cost of
“late alloHCT” are needed.  Specifically, the combination
of favorable outcomes of CBT and advances in cord blood
expansion technology may make this a more viable option
for adults.21-23 Although, this study excluded data on hap-
loidentical transplants, promising clinical outcomes to
date suggest this is as another viable means of expanding
the donor pool for adults and children with SCD.24
Ultimately, as the field advances with changes in condi-
tioning regimens, modified donor source options, and the
advent of gene therapy, ongoing analysis of outcomes and
cost will be needed.
Studies of alloHCT for SCD are also limited by the
absence of sufficient data on late effects. The risk of
impaired fertility and long-term quality of life are not well
described. Many studies have documented the impact of
alloHCT on sperm production and ovarian failure in this
population, but the actual fertility risk remains unclear
particularly in light of the use of newer reduced intensity
regimens that are less gonadotoxic.3,17,30 However, a recent
study of patients’ and parents’ attitudes toward alloHCT
documented that 56% were willing to accept infertility18
suggesting the potential for cure may far outweigh the risk
of this complication. At the same time, another recent
study of alloHCT not only reported the impact on fertility
but also on sexual function and other patient-reported
outcomes. In a cohort of individuals studied at least 10
years after transplantation for malignant disease, reports
of sexual problems, restrictions in social function, memo-
ry and attention concerns, denial of life and health insur-
ance were significant.31 Future studies should determine
late outcomes after transplantation for SCD, collecting
data not only on end-organ complications but also patient-
reported outcomes including organ function and quality of
life evaluations for both alloHCT recipients and controls.  
Finally, this study involved a USA population and its
findings cannot be easily extrapolated to a global popula-
tion. However, recent publications have documented the
impact of alloHCT throughout the developing world.
AlloHCT outcomes in India and Mexico have been
described as nearly equivalent to those in the developed
world but are performed at substantially lower costs.32,33
International experience suggests that further study of
USA transplant approaches to learn potential cost efficien-
cies from the global experience will make alloHCT more
viable for SCD and other diseases throughout the world.
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Table 4. Comparison of inpatient total adjusted costs per 30 days by
TED/PHIS patient and transplant variables during the alloHCT year
(n=176).
Variables                                            Median Total                     P
                                                         Adjusted Cost 
                                                    (IQR, $ per 30 days)                 
Patient-related                                                                    
Age                                                                                                              0.775
<10 years                                          121,506 (89,377-180,961)                 
≥10 years                                          128,731 (90,120-167,746)                 
Gender                                                                                                        0.263
Male                                                    119,492 (83,738-172,825)           
Female                                              132,841 (93,741-172,900)                 
Performance status                                                                                0.529
<80%                                                 106,761 (93,741-119,781)                 
≥80%                                                  126,343 (90,086-171,574)                 
CMV+ recipient                                                                                          0.061
Yes                                                     132,768 (104,432-190,135)          
No                                                       122,517 (83,541-156,185)                 
History of stroke                                                                                    <0.001
Yes                                                    167,746 (102,818-233,031)                
No                                                       121,506 (87,291-157,945)                 
History of VOC                                                                                           0.009
Yes                                                      135,464 (93,552-187,355)           
No                                                       111,261 (83,928-142,718)                 
History of ACS                                                                                          0.291
Yes                                                     132,841 (93,552-186,437)                 
No                                                       123,088 (84,321-171,574)                 
SCD severity                                                                                               0.022
High                                                    130,380 (93,552-201,784)           
Low                                                    112,565 (90,052-144,859)                 
Transplant-related                                                         
Donor type                                                                                               <0.001
Matched sibling                              112,835 (85,640-145,895)                 
Well-matched unrelated              246,903 (151,522-279,149)                
Cord blood                                      170,322 (102,034-217,186)                
Graft source                                                                                               0.004
Cord blood                                       170,322 (102,034-217,186)          
Bone marrow                                   120,331 (88,195-153,998)                 
Conditioning                                                                                             0.953
Non-myeloablative                         119,754 (75,011-210,103)                 
RIC (N=1)                                                        53,319                                  
Myeloablative                                  126,993 (93,746-160,187)                 
AlloHCT year                                                                                              0.001
Before 2006                                        97,416 (69,488-131,898)            
After 2006                                        135,464 (102,818-190,135)                
TED: transplant essential data; PHIS: Pediatric Health Information System; alloHCT:
allogeneic hematopoietic cell transplant; IQR: interquartile range; VOC: vaso-occlusive
crises; ACS: acute chest syndrome; RIC: reduced intensity conditioning.
Conclusion
Performing analyses of both clinical and financial out-
comes is challenging because of the lack of a single,
exhaustive data source. The data merging process is
invaluable in that it successfully utilizes existing datasets
and combines them to create the largest and most accurate
surrogate for assessment in a comprehensive manner. This
provides proof of principle for this methodology and type
of analysis and builds a foundation for future research in
the field. Specifically, the superior clinical outcomes
among children <10 years old lay the basis for prospective
studies among low-risk SCD patients for whom a MSD is
available. In addition, alloHCT, although costly, can pro-
vide a sustained decrease in healthcare utilization for
patients over time. These results and future studies will
provide guidance and insight into health policy determina-
tions for the optimal use of this curative therapy for chil-
dren with SCD.
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